ADMA Biologics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Adam S. Grossman
- Full Time Employees
- 647
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 465 State Route 17 Ramsey NJ United States of America 07446
- IPO Date
- Oct 17, 2013
- CIK
- 0001368514
- Website
- admabiologics.com
- Similar Companies
- Business
- ADMA Biologics, Inc. ADMA Biologics, Inc. (ADMA) operates as an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for treating immunodeficient patients at risk for infection and others vulnerable to certain infectious diseases; its core products include three FDA-approved immune globulin therapies—ASCENIV™ (Immune Globulin Intravenous, Human – slra 10% liquid) and BIVIGAM® (Immune Globulin Intravenous, Human) for primary humoral immunodeficiency, and NABI-HB® (Hepatitis B Immune Globulin, Human) for enhanced immunity against hepatitis B virus—supported by a vertically integrated supply chain encompassing plasma collection via approximately 10 FDA-licensed ADMA BioCenters, fractionation and purification at its cGMP-compliant Boca Raton, Florida facility with up to 600,000 liters annual capacity, and contract development and manufacturing organization services. Founded in 2004 and headquartered in Ramsey, New Jersey, the company maintains U.S.-based operations focused on the immunology and infectious disease segments, targeting physicians, hospitals, infusion centers, and specialty pharmacies with its therapies derived from human plasma rich in neutralizing antibodies via proprietary microneutralization assays. Recent developments include FDA lot release authorization in 2025 for yield-enhanced commercial batches of its immune globulins to drive gross margin expansion starting in the fourth quarter, record ASCENIV demand with statistically significant real-world reductions in infection rates for primary immunodeficiency patients, advancing payer negotiations for broader 2026 reimbursement coverage, submission of a CNPV voucher application to bolster its SG-001 pipeline program, ongoing share repurchases funded organically, and a J.P. Morgan-led debt refinancing that strengthened its balance sheet with an undrawn $225 million revolver amid third-quarter 2025 revenue of $134.2 million.
ROSEN, LEADING INVESTOR COUNSEL, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ADMA
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ADMA Biologics, Inc. of Class Action Lawsuit and Upcoming Deadlines – ADMA
ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Portnoy Law Firm Announces Class Action on Behalf of ADMA Biologics, Inc. Investors
ADMA UPCOMING DEADLINE: SueWallSt Alerts ADMA BIOLOGICS, INC. Stockholders of Securities Class Action
ADMA DEADLINE: The Gross Law Firm Reminds ADMA Biologics, Inc. Investors of Upcoming Securities Class Action Deadline
ADMA UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026
ADMA Lawsuit Notice: ADMA Biologics Channel Stuffing Allegations and 29% Stock Drop Trigger Securities Fraud Class Action
INVESTOR DEADLINE: ADMA Biologics, Inc. (ADMA) Investors with Substantial Losses Have Opportunity to Lead ADMA Investor Class Action Lawsuit – RGRD Law
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
ADMA DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages ADMA Biologics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ADMA
Bronstein, Gewirtz & Grossman LLC Urges ADMA Biologics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC Urges ADMA Biologics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
ADMA Shareholder Alert: ADMA BIOLOGICS, INC. Securities Class Action Lawsuit - Investors Should Contact Levi & Korsinsky
$ADMA Legal News: ADMA Biologics Accused of Misrepresentations about its Revenue Sources in Securities Fraud Class Action – Investors Notified to Contact BFA Law
ADMA Biologics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ADMA
ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
ADMA CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026